Alexandra Gerlach, Content Producer

Vince Sung, PharmD, MBA, BCOP, BCPS, discusses the clinical implications of the updated prostate cancer guidelines.

Darovasertib plus crizotinib boosts survival signals and response rates in HLA-A2–negative metastatic uveal melanoma, with manageable safety.

SERENA-6 shows early switch to oral SERD camizestrant plus CDK4/6 inhibitor improves PFS2, delays chemotherapy, and preserves quality of life.

Data presented at ASCO 2026 show giredestrant plus palbociclib extends PFS in ER+/HER2– metastatic breast cancer; FDA approval on the horizon.

ASCENT-04 updated data show sacituzumab govitecan plus pembrolizumab extends benefit past progression in PD-L1+ metastatic TNBC.

Elizabeth Budde, MD, discusses the phase 3 data behind the mosunetuzumab plus polatuzumab vedotin combination in the SUNMO trial.

ASCO 2026: Daraxonrasib boosts survival and PFS in metastatic pancreatic cancer versus chemo, with better tolerability and quality-of-life preservation.

ASCO 2026 data show encorafenib plus cetuximab with FOLFIRI boosts response and PFS in BRAF V600E mCRC, complementing FOLFOX.

Phase 3 SARC041 data show that abemaciclib sharply extends progression-free survival in advanced dedifferentiated liposarcoma, hinting at a new standard.

The trial met both dual primary end points of pathologic complete response and metastasis-free survival.

SARC041 data shows the clinical benefits associated with abemaciclib in the treatment of patients with incredibly rare diseases.

Apalutamide plus androgen deprivation therapy significantly increased the curative success of radical prostatectomy in patients with localized prostate cancer.

At ASCO 2026, GLORA investigators report on lisaftoclax as an addition to BTK inhibitors to deepen responses and delay progression in high-risk CLL/SLL.

Seven-year CROWN trial update shows lorlatinib delivers durable progression-free survival and strong brain control in ALK-positive NSCLC.

DREAMM-9 data show belantamab mafodotin in TI NDMM delivers high responses, with longer dosing improving eye safety and quality of life.

Enfortumab vedotin combination delivers lasting complete responses in la/mUC.

ASCO 2026 data show perioperative enfortumab vedotin plus pembrolizumab boosts EFS, OS, and pCR in cisplatin-eligible MIBC.

ASCO 2026: Glofitamab monotherapy shows durable remissions in relapsed mantle cell lymphoma after BTKi, with manageable CRS.

At ASCO 2026, CHRYSALIS-2 data show amivantamab plus lazertinib extends survival in atypical EGFR-mutated NSCLC, reshaping first-line care.

Phase 3 UTOPIA trial shows UGN-103 intravesical mitomycin after TURBT achieves 78% complete response with favorable safety.

ASCO pooled phase 3 data show that pirtobrutinib in treatment‑naive CLL/SLL delivers 93% responses, durable control, and low cardiac risk.

Tim Casey addresses what this means for health care providers and pharmacists, and why this may represent a rare window for meaningful, bipartisan reform.

Jessica Geiger, PharmD, weighs ketamine in palliative care—pain relief, opioid-sparing evidence, stigma, and safety considerations for hospice patients.

Perioperative durvalumab and tremelimumab plus neoadjuvant enfortumab vedotin improves survival in muscle-invasive bladder cancer.

Neoadjuvant pembrolizumab in colorectal cancer delivers durable, relapse-free outcomes presurgery, with ctDNA blood tests helping to predict responders.

FDA approval brings the first all-oral AML combination therapy, decitabine/cedazuridine with venetoclax, for older or unfit patients, cutting clinic visits.

Phase 1b data show zongertinib delivers durable first-line responses in HER2-mutant NSCLC, including brain metastases, with manageable safety.

Treatment with zenocutuzumab-zbco led to an overall response rate of 36.8% for a duration ranging from 2.8 to 12.9 months.

Ivermectin, vitamin D, and zinc are being recommended on social media as treatment for hantavirus—despite a lack of evidence.

Forrest N. Ridgway, PharmD, BCOP, discusses health misinformation, AI-generated medical advice, wellness culture, and the controversial therapies patients are bringing into the clinic.